In that regard, the IFN component of the ATL therapeutic regimen effectively induces the clearance of mutant ataxin-7 from the brains of spinocerebellar ataxia 7 (SCA7) mouse models, resulting in clinically relevant neurological improvements [224]. The gene discussed is IFNA1; the disease is spinocerebellar ataxia 7.